Earlier this week Dr. Ari Melnick answered another question from Targeted Oncology concerning the challenges associated with measuring tumor heterogeneity in finding new avenues for targeted therapy.
Tag: Ari Melnick MD
Dr. Ari Melnick Discusses EZH2 as a Potential Target in Diffuse Large B Cell Lymphoma
Last week Weill Cornell researcher Dr. Ari Melnick sat down with Targeted Oncology to briefly summarize the potential of EZH2 in treating diffuse large B-cell lymphoma.
Interview with the Dean: Unlocking Cancer’s Code
Dr. Laurie Glimcher, the Dean of Weill Cornell Medical College, interviewed Weill Cornell’s Dr. Ari Melnick about the cutting-edge science of unlocking human genomes and unleashing the potential for what was once unimaginable: finding a cure for cancer. Watch the interview below:
New Developments in Lymphoma 